Infliximab-dyyb

Infliximab-dyyb is administered intravenously (IV).

• Crohn's disease: The recommended dose is a 5 mg/kg at 0, 2, and 6 weeks and then 5 mg/kg every 8 weeks for Crohn's in adult or pediatric patients. Adults who initially responded but then relapsed may be treated with 10 mg/kg.
• Rheumatoid arthritis: The recommended dose for the treatment of rheumatoid arthritis is 3 mg/kg at 0, 2, and 6 weeks followed by 3 mg/kg every 8 weeks. Infliximab-dyyb should be combined with methotrexate. If response is incomplete, up to 10 mg/kg or treating every 4 weeks may be tried for this type of arthritis.
• Ulcerative colitis, psoriatic arthritis, and plaque psoriasis: are treated with a 5 mg/kg infusion at 0, 2, and 6 weeks and then 5 mg/kg every 8 weeks.
• Ankylosing spondylitis: treatment is with a 5 mg/kg infusion at 0, 2, and 6 weeks and then 5 mg/kg every 6 weeks.

• It is used with methotrexate to prevent more problems in patients with moderate to very bad rheumatoid arthritis.
• It is used to treat Crohn's disease.
• It is used to treat psoriatic arthritis.
• It is used to treat plaque psoriasis.
• It is used to treat ankylosing spondylitis.
• It is used to treat ulcerative colitis.